Related references
Note: Only part of the references are listed.Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2021)
How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Adam D. Cohen et al.
CLINICAL CANCER RESEARCH (2020)
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
Rajshekhar Chakraborty et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET (2020)
Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma
Christine Eisfeld et al.
ANNALS OF HEMATOLOGY (2020)
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model
Roman Hajek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Ola Landgren et al.
JAMA ONCOLOGY (2019)
Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation
Wen Gao et al.
ANNALS OF HEMATOLOGY (2019)
Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation
Wen Gao et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution
Victor H. Jimenez-Zepeda et al.
LEUKEMIA & LYMPHOMA (2018)
Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
Jennifer L. J. Heaney et al.
LEUKEMIA (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Is immunotherapy here to stay in multiple myeloma?
Paula Rodriguez-Otero et al.
HAEMATOLOGICA (2017)
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Veronica Gonzalez-Calle et al.
HAEMATOLOGICA (2017)
The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma
Murat Sari et al.
TURKISH JOURNAL OF HEMATOLOGY (2017)
Is immunotherapy here to stay in multiple myeloma?
Paula Rodriguez-Otero et al.
HAEMATOLOGICA (2017)
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Veronica Gonzalez-Calle et al.
HAEMATOLOGICA (2017)
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
Rasmus Sorrig et al.
PLOS ONE (2017)
Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Shaji Kumar
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma
Heinz Ludwig et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Camille Guillerey et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study
Rasmus Sorrig et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
T. Dosani et al.
BLOOD CANCER JOURNAL (2015)
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients
Eirini Katodritou et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma
E. Kastritis et al.
LEUKEMIA (2014)
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
J. A. Katzmann et al.
LEUKEMIA (2013)
New Approaches to Smoldering Myeloma
Maria-Victoria Mateos et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Share Paper
